Menu
Home > Investor Relations
Contact information of official responsible for assisting and handling investor grievances
Grievance Redressal
Name
:
Link Intime India Private Limited
Address
:
C-101, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West) Mumbai - 400083, Maharashtra, India
Tel. No.
:
+91-22-4918-6000
Fax No.
:
+91-22-4918-6060
E-mail
:
mumbai@linkintime.co.in
Website
:
www.linkintime.co.in
Contact details of the Debenture Trustee
Name
:
Vistra ITCL (India) Limited
Address
:
The IL&FS Financial Centre, Plot C- 22, G Block, 7th Floor, Bandra Kurla Complex, Bandra (East), Mumbai 400051
Tel. No.
:
+91-22-2659-3535
Fax No.
:
+91-22-2653-3297
E-mail
:
mumbai@vistra.com
Website
:
www.vistraitcl.com
 
 
Under Regulation 6, 7, 13(3)
Regulation 6(1) & 7(1) March 2024
Regulation 7(3) March 2024
Regulation 6(1) and 7(1) June 2024
Regulation 6(1) and 7(1) Sept 2024
Regulation_13(3) for Quarter ended December 2022
Regulation 13(3) for Quarter ended September 2022
Regulation 13(3) June 2022
Regulation 13(3) December 2021
Regulation 13(3) September 2021
Regulation 13(3) June 2021
Regulation 13(3) March 2019
Regulation 13(3) June 2019
Regulation 13(3) September 2019
Regulation 13 (3) - March 2020
Regulation 13 (3) - June 2020
Regulation 13 (3) - Sep 2020
Regulation 13 (3) - December, 2020
Regulation 13 (3) - March 2021
Financial Results
Audited Financial Report 2022-23
Financial Results Genlink December 2022
Financial Results Genlink September 2022
Audited Financial Report 2021-22
Unaudited financial results - March 2022
Unaudited financial results - September 2021
Unaudited financial results - March 2021
Unaudited financial results - Sep 2020
Audited financial results - March 2020
Unaudited Financial results for the half year ended September, 2019
Half yearly result March 2019
Annual result March 2019
Unaudited results for the half year ended September 30, 2018
Audited results for the year ended March 31, 2018
Unaudited results for the half year ended March 31, 2018
Unaudited results for the half year ended September 30, 2017
Audited results for the year ended March 31, 2017
Unaudited results for the half year ended March 31, 2017
Listing Compliance
19.02.2021 - Letter of change in credit rating (1)
19.02.2020 - Letter of change in credit rating (1)
Investor Complaint Under Regulation 13(3)
Compliance Certificate - Regulation 40 (9) of SEBI (LODR), 2015 for the half year ended September 30, 2018
Regulation 7 (3) of SEBI(LODR) 2015 for half year ended September 30, 2018
Regulation 13 (3) of SEBI (LODR) 2015 for quarter ended December 31, 2018
Regulation 13 (3) of SEBI (LODR) 2015 for quarter ended September 30, 2018
Regulation 13 (3) of SEBI (LODR), 2015 for the quarter ended June 30, 2018
Regulation 13 (3) of SEBI (LODR), 2015 for the quarter ended March 31, 2018
Compliance Certificate - Regulation 40 (9) of SEBI (LODR), 2015 for the half year ended March 31, 2018
Regulation 7 (3) of SEBI (LODR), 2015 for the half year ended March 31, 2018
Regulation 13 (3) of SEBI (LODR), 2015 for the quarter ended March 31, 2018
Compliance Certificate - Regulation 40 (9) of SEBI (LODR), 2015 for the half year ended March 31, 2018
Regulation 7 (3) of SEBI (LODR), 2015 for the half year ended March 31, 2017
Regulation 7 (3) of SEBI (LODR), 2015 for the half year ended September 30, 2017
Regulation 13 (3) of SEBI (LODR), 2015 for the quarter ended June 30, 2017
Regulation 13 (3) of SEBI (LODR), 2015 for the quarter ended September 30, 2017
Regulation 13 (3) of SEBI (LODR), 2015 for the quarter ended December 31, 2017
Compliance Certificate - Regulation 40 (9) of SEBI (LODR), 2015 for the half year ended March 31, 2017
Compliance Certificate - Regulation 40 (9) of SEBI (LODR), 2015 for the half year ended September 30, 2017
Others
ISIN-Reporting Sept 2024
intimation for appointment of CS under Regulation 6(1)
Scores- Reg 13(3) Investor Grievances Sept 2024
Scores - regulation 13(3) Investor Grievances June 2024
SCORES - Reg 13(3) Investor Grievances March 24
SCORES - Reg 13(3) Investor Grievances Dec 23
Resignation of Mr. Anand Shah under Regulation 51(2)
Resignation of Sumit Gupta under Regulation 51(2)
Ack Financial Results Dec-2023-7353079
Regulation 7(3) March24
Acknowledgement 13(3) March24
Acknowledment 52(7) March24
Ack Financial Results Dec-2023-7353079
Acknowledgement Reg 13(3) Dec-2023
Reg-52(7) & 7(A) Sep 2023
MGT-7A Genlink Pharma solutions Pvt Ltd 2022-23
MGT-7A Genlink Pharma solutions Pvt Ltd 2020-21
MGT-7A Genlink Pharma solutions Pvt Ltd 2021-22
Composition of the Board of Directors
March 2022
Non Repayment of Debentures Oct 2021

Genlink Pharma Solutions Pvt. Ltd.
Office No - 401, 4th Floor, Kesar Solitaire, Plot no.5, Sector 19, Sanpada, Navi -Mumbai – 400705, Maharashtra, India. | CIN No. of the Company: U74110MH2016PTC280765